Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to PDGF
News May 19, 2011
Stem Cell Therapeutics Corp. has announce that it has been granted a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,943,376- entitled, "Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells."
The claims contained within this issued patent cover methods of using PDGF to produce neural progenitor populations which can differentiate into neurons and oligodendrocytes but not astrocytes.
The use of PDGF-enriched progenitor cells can be used to treat or ameliorate neural diseases or conditions associated with neuron or oligodendrocytes loss or dysfunction, such as Stroke, Multiple Sclerosis, Traumatic brain injury, Parkinson's Disease and Alzheimer's Disease.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows: "PDGF derived neurons are a cell type that appear to be well suited for the treatment of Parkinson's Disease and potentially for other chronic neurologic disease's. This issued patent continues to add value to our intellectual property (IP) and demonstrates SCT ongoing commitment to the protection and development of its novel IP in the field of central nervous system disease."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019